Table 3.
Specific Toxicitiesa
| Toxicity | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total |
|---|---|---|---|---|---|
| Anemia | 0 (0) | 11 (23.9) | 0 (0) | 0 (0) | 11 (23.9) |
| Leukopenia | 0 (0) | 6 (13.0) | 4 (8.7) | 1 (2.2) | 11 (23.9) |
| Neutropenia | 1 (2.2) | 10 (21.7) | 19 (41.3) | 9 (19.6) | 39 (84.8) |
| Thrombocytopenia | 6 (13.0) | 3 (6.6) | 0 (0) | 0 (0) | 9 (19.6) |
| Neuromotor disorder | 3 (6.5) | 2 (4.3) | 1 (2.2) | 0 (0) | 6 (13.0) |
| Neurosensory disorder | 21 (45.7) | 7 (15.2) | 2 (4.3) | 0 (0) | 30 (65.2) |
| Abdominal pain | 0 (0) | 4 (8.7) | 1 (2.2) | 0 (0) | 5 (10.9) |
| Bone pain | 6 (13.0) | 6 (13.0) | 1 (2.2) | 0 (0) | 13 (28.2) |
| Myalgia | 11 (23.9) | 8 (17.3) | 2 (4.3) | 0 (0) | 21 (45.7) |
| Dyspnea | 0 (0) | 3 (6.6) | 2 (4.3) | 0 (0) | 5 (10.9) |
| Creatinine elevation | 6 (13.0) | 1 (2.2) | 0 (0) | 0 (0) | 7 (15.2) |
| Proteinuria | 0 (0) | 1 (2.2) | 0 (0) | 0 (0) | 1 (2.2) |
| Fatigue | 20 (43.5) | 16 (34.8) | 7 (15.2) | 0 (0) | 43 (93.5) |
| Rashes, desquamation | 4 (8.7) | 2 (4.3) | 1 (2.2) | 0 (0) | 7 (15.2) |
| Injection site reaction | 5 (11.0) | 1 (2.0) | 0 (0) | 0 (0) | 6 (13.0) |
| Hand-foot syndrome | 12 (26.1) | 7 (15.2) | 5 (10.9) | 0 (0) | 24 (52.2) |
| Anorexia | 0 (0) | 7 (15.2) | 0 (0) | 0 (0) | 7 (15.2) |
| Constipation | 0 (0) | 4 (8.7) | 0 (0) | 0 (0) | 4 (8.7) |
| Dehydration | 0 (0) | 2 (4.3) | 3 (6.6) | 0 (0) | 5 (10.9) |
| Diarrhea | 15 (32.6) | 8 (17.4) | 3 (6.5) | 1 (2.2) | 27 (58.7) |
| Nausea | 0 (0) | 4 (8.7) | 3 (6.6) | 0 (0) | 7 (15.2) |
| Oral cavity mucositis | 0 (0) | 7 (15.2) | 1 (2.2) | 0 (0) | 8 (17.4) |
| Vomiting | 0 (0) | 2 (4.3) | 3 (6.6) | 0 (0) | 5 (10.9) |
a
Values are number (percentage) of patients.